Project Grant K99HL181187
- This federal Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $159,512.00 to The Leland Stanford Junior University to conduct research on ameliorating cardiac fibrosis using human cardiac organoid models. The project aims to discover treatments for cardiac fibrosis, a hallmark of dilated cardiomyopathy, by validating potential compounds identified in a prior high-throughput screen using complex 3D cardiac organoids...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $1,505,110 to The Leland Stanford Junior University to conduct research on human pulmonary neuroendocrine cells (PNECs) and their stem cells. The key objectives are to map the innervation and molecular subtypes of human PNECs, identify their functional subsets, and characterize the cellular and molecular features of PNEC stem cells and their niches. This...
- This Project Grant award of $705,405 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to The Leland Stanford Junior University supports research focused on characterizing the role of adventitial fibroblasts in atherosclerosis. The research aims to identify new therapeutic targets and pathways related to this understudied cell population's influence on atherosclerotic plaque formation and calcification. The project will leverage single-cell genomics,...
- This federal Project Grant award of $761,017.00 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to identify and characterize human pulmonary neuroendocrine progenitor cells (NEPRs) within the distal airways and their role in airway repair and injury response. The research aims to build a foundational understanding of the anatomical distribution, molecular profiles, and functional characteristics of these rare human lung cell...
- This federal Project Grant award from the National Heart Lung and Blood Institute, under the Cardiovascular Diseases Research program (CFDA 93.837), provides $107,752 to Duke University to investigate the mechanisms of lung fibrosis. The research aims to evaluate epithelial cell-fibroblast interactions contributing to fibroblast activation through the CTHRC1-TGFβ signaling pathway, in the context of bronchiolitis obliterans and idiopathic pulmonary fibrosis. The 2-year project leverages Duke's...
- This Project Grant award, funded by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), supports research on the role of protein S-palmitoylation in TGF-beta signaling and fibrotic lung disease at Duke University. The $165,456 grant awarded on August 15, 2025 will fund a 5-year project to investigate how S-palmitoylation of the TGF-beta receptor regulates its activity and fibrotic pathways, and the potential for targeting related...
- This $638,900 Project Grant awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research at the University of California, San Francisco (UCSF) to elucidate the role of distinct fibroblast subsets in the pathogenesis of silicosis, a severe and often fatal lung disease caused by exposure to crystalline silica. The research aims to characterize the lineage trajectories and functional contributions of these unique fibroblast populations...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $410,449 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to The Leland Stanford Junior University (Stanford University) on August 1, 2025. The funding supports research to develop novel synthetic biology strategies that would enable the quantitative and dynamic regulation of growth factors and cytokines produced from human induced pluripotent stem cell-derived endothelial cells (iPSC-ECs). The goal...
- The Project Grant award titled "Alveolar Epithelial Stress Signaling in Lung Fibrosis" is funded by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) for $683,564.00 over the period of Jul 1, 2025 to Mar 31, 2030. The award supports comprehensive research focused on understanding the role of aberrant alveolar epithelial cells in the pathogenesis of pulmonary fibrosis, a devastating and progressive lung disease. The research aims to investigate...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) is providing $331,344.00 to The Leland Stanford Junior University to investigate the gene regulatory mechanisms of the coronary artery disease gene PRDM16 and its impact on smooth muscle cell phenotypic modulation. The research aims to determine how PRDM16, an epigenetic modifier, regulates the transition of smooth muscle cells into protective "fibromyocytes"...
This federal Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $161,568.00 to The Leland Stanford Junior University (Stanford University) to conduct research aimed at disaggregating and spatially profiling early-stage lung fibrosis microenvironments. The overarching goal is to utilize spatial biology and biomaterial modeling techniques to uncover the cellular and molecular drivers of early fibrogenesis in interstitial lung diseases (ILDs) in an ILD-specific manner. The project seeks to shift current paradigms by using spatial-biological data as an anatomical "blueprint" for disease- and niche-specific modeling of early fibrogenesis, enabling detailed dissection of factors contributing to scar progression. The award period runs from September 1, 2025 to August 31, 2026.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $161.6k | 8/29/25 |